This is the flagship medical device by the Singapore-based company and the first of its kind to be made available in the country
The Health Sciences Authority of Singapore (HSA) has approved Singapore medtech company Aevice Health’s flagship medical device, the AeviceMD Monitoring System.
The system is powered by a smart wearable stethoscope, which can be used to detect abnormal breath sounds and monitor vital signs including heart rate and respiratory rate. The stethoscope is said to be the first of its kind to be made available in Singapore and one of the smallest in the market globally.
Read more: Bot MD to provide AI chat assistant to over 200,000 doctors in Indonesia
The device is designed and has been approved for use in patients aged three and above. It can be used in hospitals and clinics or at home.
With the AeviceMD Monitoring System, healthcare professionals will be able to monitor digital biomarkers, track the progress of a patient’s lung health and detect issues early.
“Obtaining HSA approval represents a significant milestone for our company as we have set our sights on improving the way respiratory conditions are monitored, diagnosed and treated,” says Aevice Health CEO Adrian Ang, who is a 2019 Gen.T honouree. He adds that the company is actively engaging local partners to collaborate on pilot projects and distribution opportunities.
“This marks the beginning of an exciting journey, and we are enthusiastic about continuing our mission to create a lasting, positive impact on patients and healthcare providers in Singapore and beyond.”
Ang co-founded Aevice Health in 2016 with Nanyang Technological University professor Ser Wee, who is the company’s chief scientist. In 2020, the company launched its first wearable device, AireSone Junior, which records and analyses data about asthma symptoms in children.
See more news about the Gen.T community.